Nektar Therapeutics (NASDAQ:NKTR) Sees Strong Trading Volume After Analyst Upgrade

Nektar Therapeutics (NASDAQ:NKTR) saw unusually-strong trading volume on Wednesday after Citigroup raised their price target on the stock from $123.00 to $151.00. Citigroup currently has a buy rating on the stock. Approximately 1,039,585 shares changed hands during mid-day trading, a decline of 5% from the previous session’s volume of 1,088,839 shares.The stock last traded at $96.0290 and had previously closed at $98.16.

A number of other research analysts have also weighed in on NKTR. Weiss Ratings restated a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Monday, December 29th. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 target price on shares of Nektar Therapeutics in a research note on Monday, January 26th. Oppenheimer reaffirmed an “outperform” rating and issued a $140.00 target price on shares of Nektar Therapeutics in a research note on Friday, March 13th. William Blair raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 10th. Finally, TD Cowen initiated coverage on Nektar Therapeutics in a research note on Tuesday, March 17th. They issued a “buy” rating for the company. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Nektar Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $140.63.

Insider Activity

In related news, CEO Howard W. Robin sold 423 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the sale, the chief executive officer directly owned 75,489 shares of the company’s stock, valued at approximately $5,510,697. This trade represents a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.25% of the company’s stock.

Trending Headlines about Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Positive clinical readout: Nektar reported strong 52‑week topline results from its REZOLVE‑AA Phase 2b extension for rezpegaldesleukin (alopecia areata), which drove last session’s big rally and supports the drug’s share‑value upside if results translate to later‑stage success. Nektar posts mid-stage trial data hair loss drug
• Positive Sentiment: Analyst momentum: Multiple firms raised ratings/targets (Citigroup to $151 with a Buy, BTIG to $178, HC Wainwright upgrade, Wedbush raised its target), signaling institutional optimism and providing potential support for further upside. BTIG Research Boosts Nektar Therapeutics Price Target
• Neutral Sentiment: Conference call scheduled: Management will host a call to discuss the 52‑week topline results — useful for more detail on durability, safety and next steps, but the substance of the call will determine market reaction. Nektar to Hold Conference Call to Discuss 52-Week Topline Results
• Negative Sentiment: Dilutive secondary offering: Nektar priced an upsized $325M public offering at $92.00 per share (3,532,609 shares). The deal injects capital but increases share count and typically weighs on near‑term stock performance—especially as the offering price is near trading levels. Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
• Negative Sentiment: Legal overhang: Multiple law firms have filed or issued investor notices and class‑action filings alleging disclosure issues for the Feb–Dec 2025 period; several firms are soliciting lead‑plaintiff applicants with a May 5 deadline. The litigation risk increases uncertainty and can pressure valuation until resolved. Pomerantz Law Firm Announces Filing of Class Action

Institutional Trading of Nektar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets increased its position in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the last quarter. Deutsche Bank AG boosted its holdings in Nektar Therapeutics by 0.8% during the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock valued at $3,837,000 after acquiring an additional 743 shares during the period. Bayforest Capital Ltd boosted its holdings in Nektar Therapeutics by 51.3% during the 4th quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 862 shares during the period. FNY Investment Advisers LLC boosted its holdings in Nektar Therapeutics by 70.6% during the 3rd quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock valued at $148,000 after acquiring an additional 1,077 shares during the period. Finally, XTX Topco Ltd boosted its holdings in Nektar Therapeutics by 22.0% during the 4th quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company’s stock valued at $304,000 after acquiring an additional 1,299 shares during the period. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Trading Down 5.1%

The business has a fifty day moving average of $74.89 and a 200 day moving average of $59.10. The company has a market capitalization of $2.77 billion, a PE ratio of -9.14 and a beta of 1.16.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.91. Nektar Therapeutics had a negative return on equity of 380.32% and a negative net margin of 297.07%.The company had revenue of $21.81 million during the quarter, compared to analysts’ expectations of $10.44 million. Equities analysts forecast that Nektar Therapeutics will post -10.02 EPS for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.